Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Prices $35M Stock Offering

NEW YORK (GenomeWeb) – Trovagene today announced an offering of 4 million shares of its common stock, which is expected to bring in gross proceeds of around $35 million.

The offering is expected to close on or about July 22. Trovagene has also granted the underwriters a 30-day option to purchase up to an additional 600,000 shares.

The firm said proceeds from the offering will fund research and development, serve as working capital, and support other general corporate purposes.

Piper Jaffray and Leerink Partners are acting as joint book-running managers for the offering. Janney Montgomery Scott, Cantor Fitzgerald, and Maxim Group are co-managers on the offering.

Trovagene reported it had $44 million in cash and cash equivalents as of March 31, 2015.

Shares of the San Diego-based molecular diagnostics firm were down around 11 percent at $9.00 in Friday morning trading on the Nasdaq.   

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.